Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Survivorship Care Plans Do Not Improve Outcomes for Patients With Breast Cancer

August 16th 2011

A randomized trial comparing survivorship care plans with standard oncologist discharge visits in patients with breast cancer found no differences in outcomes among the groups.

Dr. Tripathy on the Future of Breast Cancer Meeting

August 16th 2011

Dr. Debu Tripathy from USC Norris Cancer Center Describes the Benefits of the PER Conferences

Dr. Wolff Discusses the Importance of HER2 Testing

August 15th 2011

Dr. Antonio C. Wolff from Sidney Kimmel Comprehensive Cancer Center Discusses the Importance of HER2 Testing

Dr. Tripathy on the Oncotype DX Assay Recurrence Score

August 15th 2011

Dr. Debu Tripathy from USC Norris Cancer Center on the Oncotype DX Assay Recurrence Score

Dr. O'Shaughnessy on Continued Access to Avastin

August 13th 2011

Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on Continued Access to Avastin

Dr. Tripathy Discusses Breast Cancer Gene Profiling

August 12th 2011

Dr. Debu Tripathy from USC Norris Cancer Center Discusses Breast Cancer Gene Profiling

Dr. Tripathy Discusses Breast Cancer Biomarkers

August 11th 2011

Dr. Debu Tripathy from the USC Norris Comphrensive Cancer Center Discusses Breast Cancer Biomarkers

Computer-Aided Breast Cancer Detection

August 4th 2011

Recent study findings raise questions about how well computers interpret mammograms.

In Metastatic Breast Cancer, Eribulin Safe and Effective in All Ages

August 3rd 2011

An exploratory analysis of the phase III EMBRACE trial of eribulin mesylate in metastatic breast cancer found the survival benefit and toxicity profile to be independent of age.

Dr. Kris on Patient Acceptance of Mutation Testing

August 2nd 2011

Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center Discusses Patient Acceptance of Mutation Testing

Judge Rules BRCA Genes Can Be Patented, Overturning Previous Decision

August 1st 2011

On July, 29, 2011, a US appeals court sided with Myriad Genetics, Inc's patents on the BRCA1 and BRCA2 genes.

Exemestane Is a New Option for Prevention of Breast Cancer in Postmenopausal Women

August 1st 2011

Postmenopausal women at risk of breast cancer got good news from the MAP.3 trial results: Exemestane reduced their risk of invasive breast cancer by 65% compared with placebo.

Dr. Pruthi on What She Learned From the Flaxseed Trial

August 1st 2011

Dr. Sandhya Pruthi from the Mayo Clinic in Minnesota on What She Learned From the Flaxseed Trial

Sentinel Lymph Node Test Has No Effect on Overall Survival in Women With Early-Stage Breast Cancer

July 28th 2011

It had been thought that removing the sentinel node and the surrounding lymph nodes would improve survival rates.

Dr. Pruthi Examines Options Available for Hot Flashes

July 25th 2011

Dr. Sandya Pruthi from the Mayo Clinic in Minnesota Examines the Options Available for Hot Flashes after the failure of flaxseed

Dr. Kris Explains the Use of Gene Signatures

July 25th 2011

Dr. Mark G. Kris from Memorial Sloan-Kettering cancer center Explains How Gene Signatures are Used

Ob-Gyn Physicians Support Mammograms Starting at Age 40

July 22nd 2011

The American College of Obstetricians and Gynecologists this week recommended annual mammography screenings for women starting at age 40.

Avastin Still Recommended by NCCN for Use Against Metastatic Breast Cancer

July 21st 2011

The NCCN voted to maintain the current recommendation and position on Avastin (bevacizumab) in its treatment of metastatic breast cancer.

Iniparib Fails to Improve Survival as Part of Chemotherapy in Triple-Negative Breast Cancer

July 21st 2011

The addition of the PARP inhibitor iniparib failed to improve OS or PFS when added to gemcitabine/carboplatin (GC) compared with GC alone in patients with metastatic TNBC.

FDA Advised Not to Approve Dapagliflozin for Diabetes

July 20th 2011

A panel voted 9-6 advising the FDA not to approve dapagliflozin, a diabetes drug that forces the body to dump sugar.